PL1742642T3 - Analogi fosfonianowe związków inhibitorów integrazy HIV - Google Patents

Analogi fosfonianowe związków inhibitorów integrazy HIV

Info

Publication number
PL1742642T3
PL1742642T3 PL05804767T PL05804767T PL1742642T3 PL 1742642 T3 PL1742642 T3 PL 1742642T3 PL 05804767 T PL05804767 T PL 05804767T PL 05804767 T PL05804767 T PL 05804767T PL 1742642 T3 PL1742642 T3 PL 1742642T3
Authority
PL
Poland
Prior art keywords
inhibitor compounds
integrase inhibitor
hiv integrase
phosphonate analogs
hiv
Prior art date
Application number
PL05804767T
Other languages
English (en)
Inventor
Zhenhong R Cai
Xiaowu Chen
Maria Fardis
Salman Y Jabri
Haolun Jin
Choung U Kim
Samuel E Metobo
Michael R Mish
Richard M Pastor
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of PL1742642T3 publication Critical patent/PL1742642T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548—Phosphates or phosphonates, e.g. bone-seeking
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
PL05804767T 2004-04-14 2005-04-11 Analogi fosfonianowe związków inhibitorów integrazy HIV PL1742642T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US56267804P 2004-04-14 2004-04-14
EP05804767A EP1742642B1 (en) 2004-04-14 2005-04-11 Phosphonate analogs of hiv integrase inhibitor compounds
PCT/US2005/012520 WO2005117904A2 (en) 2004-04-14 2005-04-11 Phosphonate analogs of hiv integrase inhibitor compounds

Publications (1)

Publication Number Publication Date
PL1742642T3 true PL1742642T3 (pl) 2009-06-30

Family

ID=35276373

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05804767T PL1742642T3 (pl) 2004-04-14 2005-04-11 Analogi fosfonianowe związków inhibitorów integrazy HIV

Country Status (13)

Country Link
US (2) US20080076738A1 (pl)
EP (1) EP1742642B1 (pl)
JP (1) JP2007532665A (pl)
AT (1) ATE411030T1 (pl)
AU (1) AU2005249363A1 (pl)
CA (1) CA2562713A1 (pl)
DE (1) DE602005010413D1 (pl)
DK (1) DK1742642T3 (pl)
ES (1) ES2315922T3 (pl)
PL (1) PL1742642T3 (pl)
PT (1) PT1742642E (pl)
SI (1) SI1742642T1 (pl)
WO (1) WO2005117904A2 (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004035577A2 (en) * 2002-10-16 2004-04-29 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds
EP1888581A2 (en) * 2005-05-16 2008-02-20 Gilead Sciences, Inc. Hiv-integrase inhibitor compounds
US8013159B2 (en) 2005-05-19 2011-09-06 Merck Canada Inc. Quinoline derivatives as EP4 antagonists
US20080076740A1 (en) * 2005-07-27 2008-03-27 Gilead Sciences, Inc. Antiviral compounds
WO2007096896A1 (en) * 2006-02-20 2007-08-30 Alembic Limited An improved process for the preparation of biphosphonic derivatives
WO2007136714A2 (en) * 2006-05-16 2007-11-29 Gilead Sciences, Inc. Integrase inhibitors
WO2009026206A1 (en) * 2007-08-21 2009-02-26 University Of Toledo Method for synthesizing xanthohumol
US20090291921A1 (en) * 2007-11-20 2009-11-26 Gilead Sciences, Inc. Integrase inhibitors
WO2010011815A1 (en) * 2008-07-25 2010-01-28 Smithkline Beecham Corporation Chemical compounds
CN103951643B (zh) * 2008-07-25 2015-12-09 盐野义制药株式会社 用作hiv整合酶抑制剂的化合物
SI2320908T1 (sl) * 2008-07-25 2014-05-30 Viiv Healthcare Company Predzdravila dolutegravirja
KR101733625B1 (ko) 2008-12-11 2017-05-10 시오노기세야쿠 가부시키가이샤 카르바모일피리돈 ｈｉｖ 인테그라제 억제제 및 중간체의 합성
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
UA105556C2 (uk) * 2010-01-27 2014-05-26 Віів Гелскер Компані Комбінація сполук, що містить інгібітори віл інтегрази з іншими терапевтичними агентами
TWI582097B (zh) 2010-03-23 2017-05-11 Ｖｉｉｖ醫療保健公司 製備胺甲醯吡啶酮衍生物及中間體之方法
US20120149715A1 (en) * 2010-05-28 2012-06-14 Yi Tsun Richard Kao Compounds and methods for the treatment of viral infections
JP5916730B2 (ja) * 2010-09-06 2016-05-11 グアンジョウ インスティテュート オブ バイオメディスン アンド ヘルス，チャイニーズ アカデミー オブ サイエンスィズ アミド化合物
WO2012131539A1 (en) 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
KR101365849B1 (ko) * 2012-03-28 2014-02-24 경동제약 주식회사 솔리페나신 또는 그의 염의 제조방법 및 이에 사용되는 신규 중간체
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
IL296496B2 (en) 2014-12-26 2024-10-01 Univ Emory N4-hydroxycytidine and derivatives and anti-viral uses related thereto
TN2017000342A1 (en) 2015-02-03 2019-01-16 Pfizer Novel cyclopropabenzofuranyl pyridopyrazinediones
KR102626210B1 (ko) 2017-12-07 2024-01-18 에모리 유니버시티 N4-하이드록시사이티딘 및 유도체 및 이와 관련된 항-바이러스 용도
WO2019113523A1 (en) 2017-12-08 2019-06-13 Ashok Bajji Compounds and therapeutic uses thereof
CN111484529A (zh) * 2019-01-28 2020-08-04 奥锐特药业股份有限公司 一种合成替诺福韦单苯酯的方法
CN112946154B (zh) * 2021-02-05 2022-10-25 石家庄四药有限公司 他汀类药物起始物料及其对映异构体的hplc检测方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH385846A (de) * 1960-03-31 1964-12-31 Geigy Ag J R Verfahren zur Herstellung von neuen 7-Acyl-8-hydroxy-chinolinen und ihre Verwendung als Fungizide und Bakterizide im Pflanzen- und Materialschutz
US4816570A (en) * 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) * 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
EP0481214B1 (en) * 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Prodrugs of phosphonates
US5883255A (en) * 1990-10-31 1999-03-16 Smithkline Beecham Corporation Substituted indolizino 1,2-b!quinolinones
JP3531944B2 (ja) * 1991-02-07 2004-05-31 アベンティス・ファーマ・ソシエテ・アノニム 新規のベンジル基で置換された窒素系二環式誘導体及びその製造方法
EP0520573A1 (en) * 1991-06-27 1992-12-30 Glaxo Inc. Cyclic imide derivatives
US5639881A (en) * 1991-11-08 1997-06-17 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis and elucidation of pyrimido (4,5-Q) quinazoline derivatives
TW304945B (pl) * 1992-06-27 1997-05-11 Hoechst Ag
US5798340A (en) * 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
ES2146307T3 (es) * 1993-12-17 2000-08-01 Procter & Gamble Compuestos de 6-(2-imidazolinilamino)quinolina utiles como agonistas de adrenoceptores 2-alfa.
US5538988A (en) * 1994-04-26 1996-07-23 Martinez; Gregory R. Benzocycloalkylazolethione derivatives
DE19613591A1 (de) * 1996-04-04 1997-10-09 Hoechst Ag Substituierte-Chinolin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung
US5854275A (en) * 1996-05-16 1998-12-29 Pfizer Inc. Cyclic imide derivatives
US6310211B1 (en) * 1996-09-10 2001-10-30 Pharmacia & Upjohn Company 8-hydroxy-7-substituted quinolines as anti-viral agents
DE19738005A1 (de) * 1997-08-30 1999-03-04 Bayer Ag Verwendung von substituierten 1,1-Bisphosphonaten
US6312662B1 (en) * 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
MXPA00012248A (es) * 1998-06-10 2003-04-25 Arena Pharm Inc Incrementadores de acetilcolina.
AU4719799A (en) * 1998-06-30 2000-01-17 Du Pont Pharmaceuticals Company Substituted quinolin-2(1h)-ones useful as hiv reverse transcriptase inhibitors
US6187907B1 (en) * 1998-08-31 2001-02-13 James Chen Triple helix coil template having a biologically active ligand
WO2000036132A1 (en) * 1998-12-14 2000-06-22 Merck & Co., Inc. Hiv integrase inhibitors
US6245806B1 (en) * 1999-08-03 2001-06-12 Merck & Co., Inc. HIV integrase inhibitors
WO2001027309A1 (en) * 1999-10-13 2001-04-19 Merck & Co., Inc. Hiv integrase inhibitors
PE20011349A1 (es) * 2000-06-16 2002-01-19 Upjohn Co 1-aril-4-oxo-1,4-dihidro-3-quinolincarboxamidas como agentes antivirales
US6525049B2 (en) * 2000-07-05 2003-02-25 Pharmacia & Upjohn Company Pyrroloquinolones as antiviral agents
AR036256A1 (es) * 2001-08-17 2004-08-25 Merck & Co Inc Sal sodica de un inhibidor de integrasa del vih, procesos para su preparacion, composiciones farmaceuticas que lo contienen y su uso para la manufactura de un medicamento
AU2003231765B9 (en) * 2002-04-26 2010-01-28 Gilead Sciences, Inc. Cellular accumulation of phosphonate analogs of HIV protease inhibitor compounds and the compounds as such
WO2004035577A2 (en) * 2002-10-16 2004-04-29 Gilead Sciences, Inc. Pre-organized tricyclic integrase inhibitor compounds

Also Published As

Publication number Publication date
DE602005010413D1 (de) 2008-11-27
HK1099235A1 (en) 2007-08-10
WO2005117904A3 (en) 2006-07-27
WO2005117904A2 (en) 2005-12-15
ES2315922T3 (es) 2009-04-01
EP1742642A2 (en) 2007-01-17
US20060116356A1 (en) 2006-06-01
AU2005249363A1 (en) 2005-12-15
ATE411030T1 (de) 2008-10-15
JP2007532665A (ja) 2007-11-15
CA2562713A1 (en) 2005-12-15
SI1742642T1 (sl) 2009-04-30
PT1742642E (pt) 2009-01-23
EP1742642B1 (en) 2008-10-15
DK1742642T3 (da) 2009-02-16
US20080076738A1 (en) 2008-03-27

Similar Documents

Publication Publication Date Title
SI1742642T1 (sl) Fosfonatni analogi inhibitorskih spojin HIV integraze
TW200716632A (en) Integrase inhibitor compounds
WO2004096128A3 (en) Hiv integrase inhibitors
WO2004004657A3 (en) Hiv integrase inhibitors
AP2412A (en) Phosphonate analogs of HIV inhibitor compounds.
MXPA05009969A (es) Metodo para aislar la forma cristalina i de la 5-azacitidina.
UA94833C2 (en) Substituted bicyclolactams
MX2009008275A (es) Formas polimorficas de un inhibidor macrociclico del virus de la hepatitis c.
MY141255A (en) Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs
MX2009011370A (es) Proceso para el intermediario del inhibidor proteasa de hcv.
WO2007136714A3 (en) Integrase inhibitors
MXPA05012025A (es) Imidazo y tiazolopiridinas como inhibidores de cinasa jak3.
TNSN08191A1 (en) Kinase inhibitors
MX2009009920A (es) Inhibidores no nucleosidos de transcriptasa inversa.
SE0400284D0 (sv) Novel compounds
MX2007002584A (es) Inhibidores de piridilo de senalizacion de hedgehog.
MXPA05013474A (es) Derivados de quinolilamida como antagonistas de ccr-5.
WO2009067541A3 (en) Integrase inhibitors
BR0315705A (pt) Inibidores de fosfodiesterase-4
MXPA04007396A (es) Proceso para la elaboracion de inhibidores de reductasa hmg-coa.
SI1753723T1 (sl) Substituirani kinolinski derivati kot mitotiäśni kinesinski inhibitorji
SG149880A1 (en) Novel inhibitors of chymase
TW200613289A (en) Prodrugs of hiv protease inhibitors
TW200637539A (en) CTGF inhibitors
WO2005085236A3 (en) Caspase inhibitors and uses thereof